107 related articles for article (PubMed ID: 10333714)
21. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
Kalantari MR; Ahmadnia H
Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
[TBL] [Abstract][Full Text] [Related]
22. Epithelial differentiation antigens and epidermal growth factor receptors in transitional cell bladder carcinoma: correlation with prognosis.
Nakopoulou L; Zervas A; Constantinides C; Deliveliotis C; Stefanaki K; Dimopoulos C
Urol Int; 1995; 54(4):191-7. PubMed ID: 7541921
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder.
Suzuki K; Morita T; Tokue A
Int J Urol; 2005 Feb; 12(2):152-8. PubMed ID: 15733109
[TBL] [Abstract][Full Text] [Related]
24. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
26. Expression of VEGF in urinary bladder transitional cell carcinoma in an Iraqi population subjected to depleted uranium: an immunohistochemical study.
Al-Abbasi DS; Al-Janabi AA; Al-Toriahi KM; Jabor TA; Yasseen AA
Appl Immunohistochem Mol Morphol; 2009 Jul; 17(4):307-11. PubMed ID: 19151604
[TBL] [Abstract][Full Text] [Related]
27. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
[TBL] [Abstract][Full Text] [Related]
28. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.
Yang CC; Chu KC; Yeh WM
Urol Oncol; 2004; 22(1):1-6. PubMed ID: 14969795
[TBL] [Abstract][Full Text] [Related]
29. Deletions of p15 and p16 in schistosomal bladder cancer correlate with transforming growth factor-alpha expression.
Swellam M; El-Aal AA; AbuGabel KM
Clin Biochem; 2004 Dec; 37(12):1098-104. PubMed ID: 15589816
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma.
Ping SY; Shen KH; Yu DS
Mol Carcinog; 2013 Jul; 52(7):568-79. PubMed ID: 22392726
[TBL] [Abstract][Full Text] [Related]
31. Transurethral bladder tumor resection alters fibronectin expression in transitional carcinoma cell lines.
See WA; Xu Y; Gee K; Severson C; Cohen MB; Ladehoff D
J Urol; 1997 Mar; 157(3):1136-43. PubMed ID: 9072558
[TBL] [Abstract][Full Text] [Related]
32. Translational studies of glutathione in bladder cancer cell lines and human specimens.
Pendyala L; Velagapudi S; Toth K; Zdanowicz J; Glaves D; Slocum H; Perez R; Huben R; Creaven PJ; Raghavan D
Clin Cancer Res; 1997 May; 3(5):793-8. PubMed ID: 9815751
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.
Jalali Nadoushan MR; Taheri T; Jouian N; Zaeri F
Urol J; 2007; 4(3):151-4. PubMed ID: 17987577
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of BDNF and TrkB in human bladder cancer specimens.
Lai PC; Chiu TH; Huang YT
Oncol Rep; 2010 Nov; 24(5):1265-70. PubMed ID: 20878119
[TBL] [Abstract][Full Text] [Related]
35. Expression of ERβ and its co-regulators p300 and NCoR in human transitional cell bladder cancer.
Kontos S; Papatsoris A; Kominea A; Melachrinou M; Tanoglidi A; Kachrilas S; Karavitakis M; Balampani E; Sotiropoulou-Bonikou G
Urol Int; 2011; 87(2):151-8. PubMed ID: 21525722
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma.
Choi YD; Cho NH; Ahn HS; Cho KS; Cho SY; Yang WJ
J Urol; 2007 Mar; 177(3):1174-8. PubMed ID: 17296440
[TBL] [Abstract][Full Text] [Related]
37. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
[TBL] [Abstract][Full Text] [Related]
38. Expression of beta-human chorionic gonadotropin (beta-hCG) in non-trophoblastic elements of transitional cell carcinoma of the bladder: possible relationship with the prognosis.
Bacchi CE; Coelho KI; Goldberg J
Rev Paul Med; 1993; 111(3):412-6. PubMed ID: 8108635
[TBL] [Abstract][Full Text] [Related]
39. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
40. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
